VD/VDR-vd-vdr.com

For the treatment of allergic conjunctivitis signs and symptoms

June 21, 2017

prudect name : For the treatment of allergic conjunctivitis signs and symptomsOlopatadine Synonyms: CAS NO: 113806-05-6Molecular Formula: C21H23NO3Molecular Weight: 337.41Purity: ≥99%Solubility: In DMSOStorage: −20°C 2 years web site: www.medchemexpress.com References…

📌

0💬 read more

(S)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one. ONO-4059 inhibits cell growth with IC50 of 3.59 nM, and induces cell apoptosis. The combination of of ONO-4059 with doxorubicin, etoposide, vincristine or dexamethasone causes the increased apoptosis ratio.

prudect name : (S)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one. ONO-4059 inhibits cell growth with IC50 of 3.59 nM, and induces cell apoptosis. The combination of of ONO-4059 with doxorubicin, etoposide, vincristine or dexamethasone causes the…

📌

0💬 read more

prudect name : Octreotide AcetateSynonyms: CAS NO: 79517-01-4Molecular Formula: C49H66N10O10S2Molecular Weight: 1019.24Purity: 98% minSolubility: Storage:

prudect name : Octreotide Acetate Synonyms: CAS NO: 79517-01-4Molecular Formula: C49H66N10O10S2Molecular Weight: 1019.24Purity: 98% minSolubility: Storage: -20°C web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18537937

📌

0💬 read more

prudect name : Oestradiol 17-heptanoateSynonyms: CAS NO: 4956-37-0Molecular Formula: C25H36O3Molecular Weight: 384.55Purity: 98% minSolubility: Storage:

prudect name : Oestradiol 17-heptanoate Synonyms: CAS NO: 4956-37-0Molecular Formula: C25H36O3Molecular Weight: 384.55Purity: 98% minSolubility: Storage: −20°C web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1853790

📌

0💬 read more

Olmetec; CS-866; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2¡¯-(1H-tetazol-5-yl)[1,1¡¯-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

prudect name : Olmetec; CS-866; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2¡¯-(1H-tetazol-5-yl)[1,1¡¯-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl esterOlmesartan medoxomil Synonyms: CAS NO: 144689-63-4Molecular Formula: C29H30N6O6Molecular Weight: 558.59Purity: 98% minSolubility: In DMSOStorage: -20°C web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18537880

📌

0💬 read more

Obatoclax is Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L)

prudect name : Obatoclax is Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L)Obatoclax Mesylate;…

📌

0💬 read more

OSI027 is a potent mammalian target of rapamycin (mTOR) kinase inhibitor. OSI027 has potential antineoplastic activity. MTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. MTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway. OSI027 acts as a potent suppressor of primitive leukemic precursors. OSI027 much more effective than rapamycin in eliciting antileukemic effects in vitro. OSI027 induces apoptosis of different types of cells transformed by the T315I-BCR-ABL mutation, which confers resistance to imatinib mesylate, nilotinib, and dasatinib

prudect name : OSI027 is a potent mammalian target of rapamycin (mTOR) kinase inhibitor. OSI027 has potential antineoplastic activity. MTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR…

📌

0💬 read more

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.Rigosertib is non-ATP-competitive inhibitor to PLK1 with IC50 of 9 nM. Rigosertib also exhibits inhibition against PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC50 of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 ¦ÌM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis.

prudect name : Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.Rigosertib…

📌

0💬 read more

OSI-930 is a multi-targeted tyrosine kinase inhibitor that is designed to act as a potent co-inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).OSI-930 targets both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers.

prudect name : OSI-930 is a multi-targeted tyrosine kinase inhibitor that is designed to act as a potent co-inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).OSI-930 targets…

📌

0💬 read more

8-Cyclopentyl-7,8-dihydro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-7-oxo-pyrido[2,3-d]pyrimidine-6-carbonitrile

prudect name : 8-Cyclopentyl-7,8-dihydro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-7-oxo-pyrido[2,3-d]pyrimidine-6-carbonitrileON123300 Synonyms: CAS NO: 1357470-29-1Molecular Formula: C24H27N7OMolecular Weight: 429.52Purity: 98% minSolubility: DMSOStorage: -20¡æ web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18537830

📌

0💬 read more